Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity

Objective: Glucagon/glucagon-like peptide-1 (GLP-1) receptor co-agonists may provide greater weight loss than agonists targeting the GLP-1 receptor alone. We report results from three phase 1 trials investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of the glucagon/GLP-1 r...

Full description

Bibliographic Details
Main Authors: Martin Haljeta Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, Sune Boris Nygård
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Molecular Metabolism
Subjects:
Glucagon-like peptide-1
Glucose-dependent insulinotropic polypeptide
Obesity
NN1177
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877823001357

Internet

http://www.sciencedirect.com/science/article/pii/S2212877823001357

Similar Items